Oren Livne

• Astellas in its exclusive option and license agreement with AviadoBio for an investigational gene therapy targeting frontotemporal dementia, including a USD 20 million equity investment and up to USD 30 million in option exercise payments, plus the potential for USD 2.18 billion in license fees and milestone payments plus royalties if Astellas exercises its option.

• Abbott in its global partnership to connect its continuous glucose monitoring system with Medtronic’s insulin delivery devices. 

• Astellas in its Research Collaboration and License Agreement with Elpiscience for novel bispecific macrophage engagers, including up to USD 37 million in upfront and option fees and potentially more than USD 1.7 billion in future development, regulatory, and commercial milestones.

• Galapagos on the intended transfer of its Jyseleca® business to Alfasigma, including the European and UK Marketing Authorizations, the commercial, medical and development activities for Jyseleca® and approximately 400 FTEs in 14 European countries.

• Astellas in its license agreement with 4D Molecular Therapeutics for the use of 4D's proprietary R100 vector for rare ophthalmic targets, including USD 20 million upfront and potential future option fees and milestones of up to USD 942.5 million.

• Astellas in its strategic collaboration and option agreement with Cullgen to advance innovative targeted protein degraders, with compensation potentially exceeding USD 1.9 billion if Astellas exercises all of its license options and all milestones for all programs are achieved.

• L'Oréal in its strategic partnership with Debut to develop a wide variety of novel ingredients and beauty and personal care products using Debut's proprietary cell-free and biotechnology model.

• L'Oréal in its collaboration with Verily to incorporate Verily's stabilization technology into L'Oréal's smart makeup applicator for users with limited hand and arm mobility.

• Merck Sharp & Dohme in its collaboration and license agreement with PeptiDream Inc. for the discovery and development of novel peptide drug candidates, including the potential for up to USD 2.1 billion in regulatory, development and commercial milestones.

• Vividion Therapeutics (a wholly owned and independently operated subsidiary of Bayer AG) in its strategic collaboration with Tavros Therapeutics to discover and enhance targeted oncology programs, including an upfront of USD 17.5 million, up to USD 430.5 million in milestone payments for four initial programs, and, if Vividion exercises its opt-in for up to five more targets, up to USD 482 million in additional payments.

• Bristol Myers Squibb in its research collaboration with SyntheX to discover and develop targeted protein degradation therapeutics, under which SyntheX will receive an upfront and is eligible for up to USD 550 million in performance-based milestone payments, as well as royalties on global net sales.

View All

• LES Deal of Distinction™ Award for Life Sciences in 2023 for the Astellas - Cullgen strategic collaboration and option agreement
• Shortlisted for Licensing & Collaboration Attorney of the Year, LMG Life Sciences, 2023, 2024
• Leading Life Sciences Lawyer, Licensing & Collaboration, LMG Life Sciences, 2021/22, 2022/23, 2023/24
• Rising Star, Super Lawyers New Jersey, 2020-2022
• Shortlisted for Innovative Lawyers Award Asia-Pacific, Practice of Law - Healthcare, to Baker McKenzie Healthcare & Life Sciences Group on COVID-19 Response, FT 2021 
• IFLR Europe M&A Deal of the Year 2020, European Lifestars Deal of the Year 2019 (> GBP 500 million), and Best M&A Award Large-Cap Corporate Deal 2019 (Belgium) for the Galapagos - Gilead collaboration 
• Dealmakers Award to Baker McKenzie Life Sciences Group, NJLJ Professional Excellence, 2020
• Notable Practitioner, IFLR 1000, 2020
• Rising Star, Healthcare: Life Sciences, The Legal 500 United States, 2019
• Certified Licensing Professional, 2008-2026

• New York State Bar Association
• New Jersey State Bar Association
• Licensing Executives Society